Odion T. Binitie

Dr. Odion T. Binitie


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2014 in Sarcoma
Verified
Journal Article
Open access
PDF file
CHCandace Lynn Haddox
Candace Lynn Haddox
GHGang Han
Gang Han
LALeon Anijar
Leon Anijar
OBOdion T. Binitie
Odion T. Binitie
GLG. Douglas Letson
G. Douglas Letson
DRDamon Reed
Damon Reed
Background. Little is known about how cumulative chemotherapy delivery influences the poorer outcome observed in young adult (YA, 18–40 years) versus pediatric (<18 years) osteosarcoma patients. Here, we retrospectively examined differences in presentation, therapy, including cumulative chemotherapy dose, and outcome in YA and pediatric patients.Methods. We reviewed 111 cases of high-grade osteosarcoma at Moffitt Cancer Center between 1988 and 2012. Presentation factors, therapies, and survival were compared between YA and pediatric cohorts.Results. The cohorts were equivalent with respect to metastatic status, gender, tumor size, tumor site, and histological subtype. We found that the YA patients tended to have poorer histologic response to neoadjuvant chemotherapy measured by necrosis with 55% and 35% of pediatric versus YA patients responding favorably (P=0.06). Only 39% of YA patients achieved the typical pediatric dose of methotrexate, doxorubicin, and cisplatin. These patients had a 3-year EFS of 76% (CI 53–100%) versus 47% (CI 26–69%;P=0.09) in those who received less chemotherapy.Conclusion. Age continues to be a prognostic factor in osteosarcoma. Our study suggests that presentation factors are not associated with prognosis, while poorer response to chemotherapy and lower cumulative dose of chemotherapy delivered to YA patients may contribute to poorer outcomes.

1 January 2016 in Orthopedic Clinics of North America
Verified
Journal Article
Closed access
JGJohn S. Groundland
John S. Groundland
OBOdion T. Binitie
Odion T. Binitie

6 May 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
ASAlex C Soupir
Alex C Soupir
OOOscar E. Ospina
Oscar E. Ospina
OHOliver Hampton
Oliver Hampton
MCMichelle L Churchman
Michelle L Churchman
MRMichael Radmacher
Michael Radmacher
ABAndrew S Brohl
Andrew S Brohl
Given their rarity and diversity, a fundamental understanding of the genomic underpinnings for many sarcoma subtypes is still lacking. To better define the molecular landscape of this group of diseases, we perform matched whole exome sequencing and RNA sequencing on a cohort of 1340 sarcoma tumor specimens. We identify recurrent somatic mutations and observe an increased mutational burden in metastatic vs. primary samples (p < 0.001). We observe frequent copy number alterations including whole genome doubling, with this feature being more common in metastatic tumors (p = 0.026). Estimation of immune cell abundances followed by hierarchical clustering identifies five immune subtypes ranging from low to high and we observe inferior overall survival in immune deplete clusters compared to immune enriched (p < 0.01). Interestingly, GIST predominantly form a distinct “immune intermediate” cluster that is marked by a specific enrichment for NK cells (FDR < 0.01).

16 July 2024 in Viruses
Verified
Journal Article
Open access
PDF file
TKThomas Leonidas Karadimas
Thomas Leonidas Karadimas
THThien Huong Huynh
Thien Huong Huynh
CCChloe Chose
Chloe Chose
GZGuston Zervoudakis
Guston Zervoudakis
BCBryan Clampitt
Bryan Clampitt
ALAlexander Lazarides
Alexander Lazarides
Primary bone malignancies, including osteosarcoma (OS), are rare but aggressive. Current OS treatment, involving surgical resection and chemotherapy, has improved survival for non-metastatic cases but remains ineffective for recurrent or metastatic OS. Oncolytic viral therapy (OVT) is a promising alternative, using naturally occurring or genetically modified viruses to selectively target and lyse cancer cells and induce a robust immune response against remaining OS cells. Various oncolytic viruses (OVs), such as adenovirus, herpes simplex virus, and measles virus, have demonstrated efficacy in preclinical OS models. Combining OVT with other therapeutics, such as chemotherapy or immunotherapy, may further improve outcomes. Despite these advances, challenges in reliability of preclinical models, safety, delivery, and immune response must be addressed to optimize OVT for clinical use. Future research should focus on refining delivery methods, exploring combination treatments, and clinical trials to ensure OVT’s efficacy and safety for OS. Overall, OVT represents a novel approach with the potential to drastically improve survival outcomes for patients with OS.

30 November 2022 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ACAlberto Crimì
Alberto Crimì
OBOdion T. Binitie
Odion T. Binitie
Filippo CrimiFilippo Crimi
Filippo Crimi
GLG. Douglas Letson
G. Douglas Letson
DJDavid M. Joyce
David M. Joyce
(1) Background: Pelvic Chondrosarcomas (CS) have a poor prognosis. The grade is the most important survival predictor; other factors are periacetabular location and Dedifferentiated CS subtype. The aim of the study is to investigate a series of CS of the pelvis, to analyze the prognostic factors that affect outcomes and to demonstrate how the use of intraoperative navigation can reduce the complications without worse outcomes. (2) Methods: Retrospective study on 35 patients (21 M, 14 F), median age at surgery 54 years (IQR 41–65), with pelvic CS, treated with hemipelvectomy under navigation guidance. (3) Results: 30 high-grade CS and 5 low-grade CS; mean follow-up 51.4 months. There was a positive linear correlation between the tumor volume and the presence of local recurrence at follow-up. The mean survival time of patients with larger chondrosarcoma volume was lower, but not significantly so. Lower MSTS score was associated with significantly lower survival time (p < 0.001). (4) Conclusion: in this series overall survival, LR and distant metastasis were comparable with recent literature, while complication rate was lower compared to similar series without the use of navigation. There was a correlation between tumor volume and local recurrence rate but not with the presence of metastasis at follow up.

18 January 2023 in International Orthopaedics
Verified
Journal Article
Closed access
PDF file
ACAlberto Crimì
Alberto Crimì
DJDavid Michael Joyce
David Michael Joyce
OBOdion T. Binitie
Odion T. Binitie
Pietro RuggieriPietro Ruggieri
Pietro Ruggieri
GLGeorge Douglas Letson
George Douglas Letson